Education
About Us
Working with TipRanks
Follow Us
Iovance Biotherapeutics Inc (DE:2LB)
FRANKFURT:2LB
RESEARCH TOOLSreports
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.25Last Year’s EPS
-0.3Same Quarter Last Year
Moderate Buy
Based on 15 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: -45.04%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed sentiment. While there are significant achievements like strong first-year revenue, successful international compliance, and positive market expansion prospects, these are tempered by challenges such as a decline in first-quarter revenue, manufacturing issues, a cautious revenue outlook, and increased costs.Company Guidance
During the Iovance Biotherapeutics First Quarter 2025 Financial Results Conference Call, significant guidance and metrics were outlined. The U.S. commercial launch of Amtagvi generated over $210 million in revenue in its first year, with the first quarter of 2025 alone contributing $49.3 million—$43.6 million from Amtagvi and $5.7 million from Proleukin sales. Despite a reduction in capacity due to scheduled maintenance, there was a record number of production starts in Q2. The revised full-year revenue guidance for 2025 is set between $250 million and $300 million, with expectations for 100-110 commercial patient infusions in Q2. Gross margins are projected to exceed 70% in the coming years. Additionally, the company anticipates potential approvals for Amtagvi in the UK, Canada, and the EU, further expanding its market presence.First Year U.S. Launch Revenue
Generated more than $210 million in revenue in the first 12 months of the U.S. launch of Amtagvi, with infusions from nearly 300 patients.
Successful EMA Inspections
EMA inspected and confirmed that the ICTC and contract manufacturers are GMP-compliant, supporting upcoming EU approval of Amtagvi.
Strong Commercial Network
70 ATCs are part of the treatment network with 79% completing tumor resections, indicating a strong foundation for growth.
Positive Market Expansion Prospects
Anticipated approvals for Amtagvi in the United Kingdom, Canada, and the European Union, with additional submissions in Australia and Switzerland.
DE:2LB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:2LB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | €2.80 | €2.80 | 0.00% |
Feb 27, 2025 | €5.13 | €3.96 | -22.81% |
Nov 07, 2024 | €11.52 | €9.10 | -20.97% |
Aug 08, 2024 | €6.69 | €9.10 | +36.02% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Iovance Biotherapeutics Inc (DE:2LB) report earnings?
Iovance Biotherapeutics Inc (DE:2LB) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Iovance Biotherapeutics Inc (DE:2LB) earnings time?
Iovance Biotherapeutics Inc (DE:2LB) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Iovance Biotherapeutics Inc stock?
The P/E ratio of Iovance Biotherapeutics is N/A.
What is DE:2LB EPS forecast?
DE:2LB EPS forecast for the fiscal quarter 2025 (Q2) is -0.25.